An Expanded Access Protocol for Mobocertinib in Refractory Non-small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Exon20 Insertion Mutations
Clinical trial NCT04535557 · APPROVED_FOR_MARKETING
Trial details
- NCT number
- NCT04535557
- Sponsor
- Millennium Pharmaceuticals, Inc.
- Status
- APPROVED_FOR_MARKETING
- Study type
- EXPANDED_ACCESS
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.